Erasmus MC

Medicine & Life Sciences

1. Netherlands 100%
2. Systematic Reviews 81%
3. Cohort Studies 60%
4. Meta-Analysis 59%
5. Therapeutics 56%
6. Child 53%
7. Population 51%
8. Neoplasms 49%
9. Randomized Controlled Trials 44%
10. Coronavirus 37%
11. SARS Virus 36%
12. Survival 33%
13. Confidence Intervals 32%
14. Health 31%
15. Pandemics 31%
16. Pediatrics 30%
17. Mortality 30%
18. Guidelines 29%
19. Pregnancy 28%
20. Genes 28%
21. Quality of Life 28%
22. Brain 27%
23. Delivery of Health Care 27%
24. Registries 27%
25. Cost-Benefit Analysis 26%
26. Biomarkers 26%
27. Infections 25%
28. Prostatic Neoplasms 25%
29. Mothers 24%
30. Stroke 24%
31. Prospective Studies 24%
32. Mutation 24%
33. Incidence 23%
34. Multicenter Studies 23%
35. Costs and Cost Analysis 23%
36. Pain 22%
37. Observational Studies 22%
38. Breast Neoplasms 20%
39. Pharmaceutical Preparations 20%
40. Safety 19%
41. Kidney 19%
42. Odds Ratio 18%
43. Colorectal Neoplasms 18%
44. Phenotype 18%
45. Early Detection of Cancer 18%
46. Genome 17%
47. Pharmacokinetics 17%
48. Neoplasm Metastasis 17%
49. Databases 16%
50. Genome-Wide Association Study 16%
51. Recurrence 16%
52. Patient Reported Outcome Measures 16%
53. Magnetic Resonance Imaging 16%
54. Cross-Sectional Studies 16%
55. Organoids 16%
56. Retrospective Studies 16%
57. Mental Health 16%
58. Depression 15%
59. Wounds and Injuries 15%
60. Health Care Outcome Assessment 15%
61. Lung 15%
62. Transplants 15%
63. Osteoarthritis 15%
64. Liver 15%
65. Datasets 14%
66. Disease Outbreaks 14%
67. Low Back Pain 14%
68. Severe Acute Respiratory Syndrome 14%
69. DNA Methylation 14%
70. Dementia 14%
71. Viruses 13%
72. Exercise 13%
73. Critical Illness 13%
74. Equipment and Supplies 13%
75. Serum 13%
76. Intensive Care Units 13%
77. Proteins 13%
78. Drug Therapy 13%
79. Anti-Bacterial Agents 13%
80. Education 13%
81. Newborn Infant 13%
82. Traumatic Brain Injury 13%
83. Clinical Trials 12%
84. Data Analysis 12%
85. Radiotherapy 12%
86. Parturition 12%
87. T-Lymphocytes 12%
88. Cardiovascular Diseases 12%
89. Biopsy 11%
90. Knee Osteoarthritis 11%
91. Growth 11%
92. Logistic Models 11%
93. Blood Pressure 11%
94. Body Mass Index 11%
95. Intellectual Disability 11%
96. Alzheimer Disease 11%
97. Placebos 11%
98. Cognitive Dysfunction 11%
99. Referral and Consultation 11%
100. Antibodies 11%